Lancet Oncology
Papers 8907
1 page of 891 pages (8,907 results)
#1Jose Perez-GarciaH-Index: 20
#2Geraldine Gebhart (ULB: Université libre de Bruxelles)H-Index: 9
Last. Trial InvestigatorsH-Index: 1
view all 23 authors...
Summary Background Several de-escalation approaches are under investigation in patients with HER2-positive, early-stage breast cancer. We assessed early metabolic responses to neoadjuvant trastuzumab and pertuzumab using 18F-fluorodeoxyglucose (18F-FDG)-PET (18F-FDG-PET) and the possibility of chemotherapy de-escalation using a pathological response-adapted strategy. Methods We did a multicentre, randomised, open-label, non-comparative, phase 2 trial in 45 hospitals in Spain, France, Belgium, Ge...
#1Boris Sepesi (University of Texas MD Anderson Cancer Center)H-Index: 22
#2Tina Cascone (University of Texas MD Anderson Cancer Center)H-Index: 26
#1Nasser K. Altorki (NewYork–Presbyterian Hospital)H-Index: 64
#2Timothy E. McGraw (NewYork–Presbyterian Hospital)H-Index: 49
Last. Silvia C. Formenti (NewYork–Presbyterian Hospital)H-Index: 70
view all 19 authors...
Summary Background Previous phase 2 trials of neoadjuvant anti-PD-1 or anti-PD-L1 monotherapy in patients with early-stage non-small-cell lung cancer have reported major pathological response rates in the range of 15–45%. Evidence suggests that stereotactic body radiotherapy might be a potent immunomodulator in advanced non-small-cell lung cancer (NSCLC). In this trial, we aimed to evaluate the use of stereotactic body radiotherapy in patients with early-stage NSCLC as an immunomodulator to enha...
#1Hikaru Sasaki (Keio: Keio University)H-Index: 17
#1Martin J. van den Bent (EUR: Erasmus University Rotterdam)H-Index: 78
#2C Mircea S Tesileanu (EUR: Erasmus University Rotterdam)H-Index: 1
Last. Brigitta G. Baumert (UM: Maastricht University)H-Index: 42
view all 41 authors...
Summary Background The CATNON trial investigated the addition of concurrent, adjuvant, and both current and adjuvant temozolomide to radiotherapy in adults with newly diagnosed 1p/19q non-co-deleted anaplastic gliomas. The benefit of concurrent temozolomide chemotherapy and relevance of mutations in the IDH1 and IDH2 genes remain unclear. Methods This randomised, open-label, phase 3 study done in 137 institutions across Australia, Europe, and North America included patients aged 18 years or olde...
#1Alexander J. Stratigos (UoA: National and Kapodistrian University of Athens)H-Index: 38
#2Aleksandar Sekulic (Mayo Clinic)H-Index: 25
Last. Matthew G. Fury (Regeneron)H-Index: 33
view all 38 authors...
Summary Background Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy. Cemiplimab, a PD-1 antibody, is approved for treatment of advanced cutaneous squamous cell carcinoma and has shown clinical activity as monotherapy in first-line non-small-cell lung cancer. Here, we present the primary analysis data of cemiplimab in patients with locally advanced basal cell carcinoma after HHI therapy. Meth...
#1Evan Y. Yu (UW: University of Washington)H-Index: 39
#2Daniel P. Petrylak (Yale Cancer Center)H-Index: 41
Last. Arjun Vasant BalarH-Index: 19
view all 20 authors...
Summary Background Locally advanced or metastatic urothelial carcinoma is generally incurable and has scarce treatment options, especially for cisplatin-ineligible patients previously treated with PD-1 or PD-L1 therapy. Enfortumab vedotin is an antibody–drug conjugate directed at Nectin-4, a protein highly expressed in urothelial carcinoma. We aimed to evaluate the efficacy and safety of enfortumab vedotin in the post-immunotherapy setting in cisplatin-ineligible patients. Methods EV-201 is a mu...
1 CitationsSource
#1Kami J. Maddocks (OSU: Ohio State University)H-Index: 30
Top fields of study
Breast cancer